Substituted pyridine compounds as crac modulators

Abstract

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

We claim: 
     
         1 . A compound having the Formula (I): 
       
         
           
           
               
               
           
         
         wherein, 
         ring A ismonocyclic heteroaryl provided that the ring A is not pyrazolyl; 
         ring E is a 5-membered non aromatic heterocyclic ring selected from 
       
       
         
           
           
               
               
           
         
         X, at each occurrence, is independently selected from —C(O)—, —CR 4 R 5 — and —NR—; 
         Y, at each occurrence, is independently —C(O)— or —CR 4 R 5 —; 
         provided that both of X and Y are not simultaneously —C(O)—; 
         R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, —C(O)NR 6 R 7 , —C(O)OR 8  and —C(O)R 9 ; 
         ring W is selected from aryl or heteroaryl; 
         L is selected from —C(O)NR 11 —, —NR 11 C(O)— and —NR 11 CH 2 —; 
         ring D is selected from 
       
       
         
           
           
               
               
           
         
         wherein A 1  and A 2  are independently CR 3  or N; 
         G is selected from S, NR 12  and O; 
         R 1 , which may be same or different at each occurrence, is independently selected from halogen, cyano, nitro, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy and substituted or unsubstituted cycloalkyl; 
         R 2 , which may be same or different at each occurrence, is independently selected from halogen, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkoxy, —NR 6 R 7  and —NHC(O)R 9 ; 
         R 3 , which may be same or different at each occurrence, is independently selected from hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, substituted or unsubstituted haloalkoxy, substituted or unsubstituted cycloalkyl, —NR 6 R 7 , —C(O)NR 6 R 7  and —C(O)OR 8 ; 
         R 4  and R 5 , which may be same or different at each occurrence, are independently selected from hydrogen, halogen, —OR 10 , substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, —C(O)OR 8 , —C(O)—NR 6 R 7 , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclyl; provided that, when any of R 4  or R 5  in Y is —OR 10  then R 10  is not hydrogen; 
         R 6  and R 7 , which may be same or different at each occurrence, are independently selected from hydrogen, substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl; or R 6  and R 7 , together with the nitrogen atom to which they are attached, may form a substituted or unsubstituted, saturated or unsaturated 3 to 12 membered cyclic ring, wherein the unsaturated cyclic ring may have one or two double bonds; 
         R 8 , which may be same or different at each occurrence, is independently hydrogen, substituted or unsubstituted alkyl; 
         R 9 , which may be same or different at each occurrence, is independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted aryl; 
         R 10  is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclyl; 
         R 11 , at each occurrence, is independently selected from hydrogen, substituted or unsubstituted alkyl and substituted or unsubstituted aryl; 
         R 12  is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclyl; 
         ‘n’ is an integer ranging from 0 to 2, both inclusive; 
         ‘p’ is an integer ranging from 0 to 4, both inclusive; and 
         ‘q’ is an integer ranging from 1 to 2, both inclusive; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The compound of  claim 1 , having Formula (II) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein, L is selected from —C(O)NH—, —NHC(O)— and —NHCH 2 —; 
         ring W is selected from aryl or heteroaryl; 
         ring D, X, Y, R 1 , R 2 , R 3 , ‘n’, ‘p’, and ‘q’ are as defined in claim- 1 . 
       
     
     
         3 . The compound of  claim 1 , having Formula (III) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein, L is selected from —C(O)NH—, —NHC(O)— and —NHCH 2 —; 
         ring W is selected from aryl or heteroaryl; 
         ring D, X, Y, R 1 , R 2 , R 3 , ‘n’, ‘p’, and ‘q’ are as defined in claim- 1 . 
       
     
     
         4 . The compound of  claim 1 , wherein ring 
       
         
           
           
               
               
           
         
       
       is selected from Formula (i) to (iii) 
       
         
           
           
               
               
           
         
         wherein R, R 4 , and R 5  are as defined in claim- 1 . 
       
     
     
         5 . The compound of  claim 1 , wherein ring 
       
         
           
           
               
               
           
         
       
       is selected from Formula (iv) to (vii) 
       
         
           
           
               
               
           
         
         where R, R 4 , R 5  and R 10  are as defined  claim 1 . 
       
     
     
         6 . The compound of  claim 1 , wherein L is —C(O)NR 11 —, —NR 11 C(O)— or —NR 11 CH 2 —;
 wherein R 11  is hydrogen or substituted or unsubstituted alkyl. 
 
     
     
         7 . The compound of  claim 1 , wherein ring W is aryl wherein the aryl is phenyl. 
     
     
         8 . The compound of  claim 1 , wherein ring W is heteroaryl wherein the heteroaryl is pyridyl, oxazolyl, isoxazolyl or thiadiazolyl. 
     
     
         9 . The compound of  claim 1 , wherein R 1  is selected from halogen, cyano, nitro, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy and substituted or unsubstituted cycloalkyl; and ‘p’ is 0, 1, 2, or 3. 
     
     
         10 . The compound of  claim 1 , wherein ring D is 
       
         
           
           
               
               
           
         
       
       wherein A 1  and A 2  are independently selected from CR 3  or N; R 3  is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl and substituted or unsubstituted cycloalkyl; and ‘q’ is 1 or 2. 
     
     
         11 . The compound of  claim 1 , wherein ring is 
       
         
           
           
               
               
           
         
       
       where G is selected from S, NR 12  and O; wherein R 12  is hydrogen or substituted or unsubstituted alkyl; 
     
     
         12 . The compound of  claim 1 , wherein R 3  is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl and substituted or unsubstituted cycloalkyl; and ‘q’ is 1 or 2. 
     
     
         13 . The compound of  claim 1 , wherein R 2  is selected from halogen, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted cycloalkyl, and —NR 6 R 7  where R 6  and R 7  are independently a hydrogen or substituted or unsubstituted alkyl; and ‘n’ is 0, 1 or 2. 
     
     
         14 . The compound of  claim 1 , having the Formula (IV): 
       
         
           
           
               
               
           
         
         wherein R is substituted or unsubstituted alkyl; substituted or unsubstituted haloalkyl, or substituted or unsubstituted cycloalkyl; L is —C(O)NH—, —NHC(O)—, or —NHCH 2 —; ring W is phenyl, pyridyl, oxazolyl, isoxazolyl or thiadiazolyl; R 1  may be same or different and are independently a halogen, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl or substituted or unsubstituted cycloalkyl; ‘p’ is 1, 2, or 3; ring D is 
       
       
         
           
           
               
               
           
         
         R 3  is hydrogen, halogen, substituted or unsubstituted alkyl; ‘q’ is 1; R 2  is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted cycloalkyl, and —NR 6 R 7  where R 6  and R 7  are independently a hydrogen or substituted or unsubstituted alkyl; and ‘n’ is 0, 1 or 2. 
       
     
     
         15 . The compound of  claim 1 , which is selected from:
 2,6-Difluoro-N-(4-(2-methyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)benzamide;   N-(4-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl) phenyl)-2,6-difluorobenzamide;   N-(2,6-Difluorophenyl)-4-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)benzamide;   N-(4-(2-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)-2,6-difluorobenzamide;   4-(2-cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-N-(2,6-difluorophenyl)benzamide;   2,6-Difluoro-N-(4-(2-methoxy-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)benzamide;   2,6-difluoro-N-(4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)pyridin-3-yl)phenyl) benzamide;   2,6-difluoro-N-(3-methyl-4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)pyridin-3-yl)phenyl) benzamide;   2-Chloro-6-fluoro-N-(4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)pyridin-3-yl)phenyl)benzamide;   2,6-Difluoro-N-(4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(methylamino)pyridin-3-yl)phenyl)benzamide;   2-Chloro-6-fluoro-N-(4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(methylamino)pyridin-3-yl)phenyl)benzamide;   2-Fluoro-6-methyl-N-(4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(methylamino)pyridin-3-yl)phenyl)benzamide;   2,6-Difluoro-N-(3-methyl-4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(methylamino)pyridin-3-yl)phenyl)benzamide;   2,6-Difluoro-N-(4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)benzamide;   2,6-Difluoro-N-(3-methyl-4-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)benzamide;   N-(4-(4-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)-2,6-difluorobenzamide;   N-(2,6-Difluorophenyl)-4-(4-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)benzamide;   N-(4-(3-Ethyl-4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)-2,6-difluorobenzamide;   N-(2,6-Difluorophenyl)-4-(3-ethyl-4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)benzamide;   2,6-Difluoro-N-(4-(3-methyl-4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)benzamide;   N-(4-(5-Ethyl-4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)-2,6-difluorobenzamide;   N-(2,6-Difluorophenyl)-4-(5-ethyl-4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)benzamide;   2,6-Difluoro-N-(4-(6-methyl-4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)benzamide;   N-(4-(4-Chloro-6-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)-2,6-difluorobenzamide;   N-(4-(4-Ethoxy-6-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)-2,6-difluorobenzamide;   2,6-Difluoro-N-(4-(2-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl)phenyl)benzamide;   2,6-Difluoro-N-(4-(4-methyl-6-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)benzamide;   N-(4-(2-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) pyridin-3-yl)phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide;   N-(4-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-3-methylphenyl)-2, 6-difluorobenzamide;   N-(2′-ethyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[3,3′-bipyridin]-6-yl)-2,6-difluorobenzamide;   N-(2′-ethyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[2,3′-bipyridin]-5-yl)-2,6-difluorobenzamide;   N-(4-(2-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-3-methylphenyl)-2,6-difluorobenzamide;   N-(5-(2-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)pyrazin-2-yl)-2, 6-difluorobenzamide;   2-Chloro-N-(5-(2-cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)pyrazin-2-yl)-6-fluorobenzamide;   N-(2′-Cyclopropyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[2,3′-bipyridin]-5-yl)-2,6-difluorobenzamide;   N-(2′-Cyclopropyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[3,3′-bipyridin]-6-yl)-2,6-difluorobenzamide;   2,6-Difluoro-N-(5-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)benzamide;   2,6-Difluoro-N-(5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2′-(trifluoromethyl)-[3,3′-bipyridin]-6-yl)benzamide;   2,6-Difluoro-N-(5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2′-(trifluoromethyl)-[2,3′-bipyridin]-5-yl)benzamide;   5-(5-((2,6-Difluoro benzyl)amino)-2′-ethyl-[2,3′-bipyridin]-5′-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;   5-(6′-((2,6-Difluorobenzyl) amino)-2-ethyl-[3,3′-bipyridin]-5-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;   N-(2′-Ethyl-4-methyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[2,3′-bipyridin]-5-yl)-2,6-difluorobenzamide;   N-(2′-Ethyl-4-methyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[3,3′-bipyridin]-6-yl)-2,6-difluorobenzamide;   N-(2-Chloro-6-fluorophenyl)-5-(2-cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)thiophene-2-carboxamide;   5-(2-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-N-(3-methylpyridin-4-yl)thiophene-2-carboxamide;   N-(2,6-Difluorophenyl)-5-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)furan-2-carboxamide;   5-(2-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-N-(2,6-difluorophenyl)furan-2-carboxamide;   N-(4-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)-3,5-difluoroisonicotinamide;   N-(4-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)-2-fluoro-6-methylbenzamide;   2-Chloro-N-(4-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) pyridin-3-yl)phenyl)-6-fluorobenzamide;   N-(4-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl) phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide;   N-(4-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)-3,5-dimethylisoxazole-4-carboxamide;   N-(4-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl) phenyl)-3-methylisonicotinamide;   N-(4-(5-(4,4-Dimethyl-5-oxo-4,5-dihydroisoxazol-3-yl)-2-ethylpyridin-3-yl)phenyl)-2,6-difluorobenzamide;   2,6-Difluoro-N-(5-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)pyrazin-2-yl)benzamide;   2-Chloro-N-(5-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)pyrazin-2-yl)-6-fluorobenzamide;   2,6-Difluoro-N-(5-(2-methyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)pyrazin-2-yl)benzamide;   2,6-Difluoro-N-(5-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(methylamino)pyridin-3-yl)pyrazin-2-yl)benzamide;   N-(2,6-Difluorophenyl)-5-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)thiophene-2-carboxamide;   N-(2,6-Difluorophenyl)-5-(2-methyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)thiophene-2-carboxamide;   5-(2-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-N-(2,6-difluorophenyl)thiophene-2-carboxamide;   N-(2,6-Difluorophenyl)-5-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)pyridin-3-yl)thiophene-2-carboxamide;   N-(2,6-Difluorophenyl)-5-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(methylamino)pyridin-3-yl)thiophene-2-carboxamide;   N-(2,6-Difluorophenyl)-1-methyl-5-(2-methyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1H-pyrrole-2-carboxamide;   N-(2,6-Difluorophenyl)-5-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1-methyl-1H-pyrrole-2-carboxamide   N-(4-(4-Ethyl-6-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)-2,6-difluorobenzamide;   N-(4-(3-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl)-2,6-difluorobenzamide;   N-(4-(3-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) pyridin-2-yl)phenyl)-2,6-difluorobenzamide;   N-(4-(5-Cyclopropyl-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) pyridin-2-yl)phenyl)-2,6-difluorobenzamide and   N-(4-(6-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl)-2,6-difluorobenzamide
 or pharmaceutically acceptable salt thereof. 
   
     
     
         16 . A pharmaceutical composition comprising one or more compounds of Formula (I) according to  claim 1 , and one or more pharmaceutically acceptable excipients. 
     
     
         17 . A method of treating, managing and/or lessening diseases or disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel in a subject in need thereof wherein the method comprises administering to the subject a therapeutically effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         18 . The method of  claim 17 , wherein the diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel are selected from the group consisting of inflammatory diseases, autoimmune diseases, allergic disorders, organ transplant, cancer and cardiovascular disorders. 
     
     
         19 . The method of  claim 17 , wherein the disease is rheumatoid arthritis, multiple sclerosis and psoriasis. 
     
     
         20 . The method of  claim 17 , wherein the disease is allergic disorders selected from asthma, chronic obstructive pulmonary disorder (COPD) or respiratory disorders. 
     
     
         21 . The method of  claim 18 , wherein inflammatory diseases are selected from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases, pancreatitis, peripheral neuropathy, multiple sclerosis (MS) and inflammation associated with cancer. 
     
     
         22 . A process for the preparation of a compound of Formula (I): 
       
         
           
           
               
               
           
         
         where ring A, ring D, ring E, ring W, L, R 1 , R 2 , R 3 , ‘n’, ‘p’, and ‘q’ are as described herein above, 
         the process comprising the steps: 
       
       a) coupling of a borate compound of Formula (1) with halo compound of Formula (2) where X′ is halogen, to give compound of Formula (I) by using suitable reagents Pd(PPh 3 ) 2 Cl 2 , Pd 2 dba 3 , Pd(PPh 3 ) 4 , or Pd(OAc) 2  and a suitable ligand 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), xanthophos, or triphenylphosine 
       
         
           
           
               
               
           
         
       
       b) alternatively, 
       coupling of a halo compound of Formula (3) where X′ is halogen, with compound of Formula (2) where p is pinacolatoboronate or stannane, to give compound of Formula (I) by using suitable reagents Pd(PPh 3 ) 2 Cl 2 , Pd 2 dba 3 , Pd(PPh 3 ) 4 , or Pd(OAc) 2  and a suitable ligand 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), xanthophos, or triphenylphosphine